Cagrilintide
Long-Acting Amylin Analogue
Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk as the amylin half of CagriSema — the combination of cagrilintide + semaglutide 2.4mg being studied as a next step beyond Wegovy. Amylin is a pancreatic hormone secreted with insulin that regulates post-meal satiety — a pathway entirely separate from GLP-1.
At a Glance
Amylin complements GLP-1 by acting on different brain regions and through different signaling pathways. GLP-1 reduces hunger primarily via the hypothalamus and brainstem; amylin acts on the area postrema and nucleus accumbens — affecting not just hunger but also the reward value of food and meal duration.
The combination produces what appears to be synergistic rather than merely additive weight loss — the SCALE NEXT trial of CagriSema showed 22.7% mean body weight reduction at 68 weeks, approaching tirzepatide's outcomes from a completely different mechanistic pairing.
Phase 3 REDEFINE trials are ongoing, positioning CagriSema as a potential successor to or combination partner for semaglutide in the obesity treatment pipeline.
This compound operates through several converging biological pathways, which helps explain the breadth of effects observed across different tissue and metabolic models.
Amylin Receptor Agonism
Activates calcitonin receptor/RAMP complexes in the area postrema and nucleus accumbens — brain regions governing meal termination and food reward.
Area Postrema Satiety
Acts on the area postrema (outside the blood-brain barrier) to signal meal completion — a different CNS access point from GLP-1's hypothalamic action.
Long-Acting Design
Fatty acid conjugation enables once-weekly dosing — matched to semaglutide's dosing interval for convenient combination research.
Complementary to GLP-1
Non-overlapping mechanism with GLP-1 agonists — each activates different receptors in different brain regions, producing additive or synergistic satiety effects.
Preclinical and clinical models have investigated this compound across a wide range of physiological contexts and tissue types.
- Obesity weight loss — CagriSema Phase 2/3 showing ~22.7% body weight reduction
- Amylin mechanism research — area postrema satiety signaling independent of GLP-1
- Combination with semaglutide — dual satiety pathway activation studies
- Food reward and eating behavior — nucleus accumbens amylin receptor role
- Meal termination signals — post-meal satiety duration research
- Type 2 diabetes — glycemic control via amylin's glucagon suppression
- Next-generation obesity treatment research — beyond single-mechanism GLP-1
Cagrilintide's value in research is largely defined by its combination with semaglutide — demonstrating that non-overlapping satiety mechanisms can be combined for synergistic outcomes.
Cagrilintide, pramlintide, and semaglutide illustrate the evolution of amylin research — from short-acting standalone to long-acting combination that rivals surgical outcomes.
| Aspect | Cagrilintide | Pramlintide (reference) | Semaglutide |
|---|---|---|---|
| Type | Long-acting amylin analogue | Short-acting amylin analogue | GLP-1 agonist |
| Dosing | Once weekly | 3x daily | Once weekly |
| Brain Target | Area postrema, NAcc | Area postrema | Hypothalamus, brainstem |
| Approval | Phase 3 / not approved | FDA approved (T1/T2D) | FDA approved |
| Weight Loss | 22.7% (CagriSema combo) | ~3–4% (standalone) | ~15–17% |
The following reflects findings from published preclinical and clinical safety assessments where available.
Synergistic with GLP-1 — non-overlapping mechanism produces additive/synergistic weight loss in Phase 2/3
Once-weekly dosing — matched to semaglutide for convenient combination protocol
Phase 3 data incoming — REDEFINE program will provide definitive efficacy and safety data
Limited standalone data — primarily studied as part of CagriSema; standalone efficacy modest; dependent on combination context
This overview is strictly educational and based on publicly available scientific literature as of 2026. It does not constitute medical advice. All Helixera Labs products are for laboratory research use only. Not for human or veterinary use. · Helixera Labs LLC © 2026